Clinical Trials Logo

Filter by:
NCT ID: NCT05342974 Active, not recruiting - Abortion Early Clinical Trials

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

Start date: April 19, 2022
Phase: Early Phase 1
Study type: Interventional

Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.

NCT ID: NCT05342753 Active, not recruiting - Lip Augmentation Clinical Trials

Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects

Start date: June 13, 2022
Phase: N/A
Study type: Interventional

Open-label, phase IV, post-marketing study to evaluate aesthetic improvement in Chinese subjects after treatment with Restylane Kysse.

NCT ID: NCT05342519 Active, not recruiting - Vitiligo Clinical Trials

Daily Topical Rapamycin for Vitiligo

Start date: July 28, 2022
Phase: Phase 2
Study type: Interventional

In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.

NCT ID: NCT05340621 Active, not recruiting - Melanoma Clinical Trials

NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Start date: May 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.

NCT ID: NCT05339594 Active, not recruiting - Clinical trials for Peripheral Nerve Injuries

REINVENT Registry (Registry of the Nerve Gap Repair From Integra)

Start date: May 30, 2022
Phase:
Study type: Observational [Patient Registry]

This is a prospective, multi-center, observational registry designed to evaluate two of Integra's collagen nerve gap repair products (NeuraGen® Nerve Guide and NeuraGen® 3D Nerve Guide Matrix). This registry will collect data on the outcome measures throughout the follow-up period for each patient. Data will be collected per standard of care.

NCT ID: NCT05339464 Active, not recruiting - Health Behavior Clinical Trials

Ready and Healthy for Kindergarten

Start date: May 9, 2022
Phase: N/A
Study type: Interventional

This study pilot tests a family wellness program that promotes academic and physical readiness for school among Latino dual language learners using a mixed methods and community engaged approach.

NCT ID: NCT05338970 Active, not recruiting - Clinical trials for Nonsquamous Non-small Cell Lung Cancer

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Start date: July 8, 2022
Phase: Phase 3
Study type: Interventional

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

NCT ID: NCT05338437 Active, not recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

NMES in HF Patients to Improve Functional Recovery Following Hospitalization

NeuHFRecover
Start date: February 7, 2022
Phase: N/A
Study type: Interventional

The goal of this research study is to understand whether an at-home exercise program started after hospitalization for HFpEF, and continuing for 4 weeks following discharge from the hospital, can preserve or improve physical function.

NCT ID: NCT05338385 Active, not recruiting - ACL Tear Clinical Trials

Readiness Outcomes Affecting Return to Sport 2.0: An Intervention Feasibility & Pilot Study

ROAR 2:Pilot
Start date: May 3, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the feasibility of implementing a mental skills training intervention for adolescent athletes who tear their ACL and undergo ACL reconstruction surgery alongside receiving standard-of-care clinical treatment. The study will also determine if the mental skills coaching program has any effect on the psychological readiness of patients to return to sport after undergoing surgery and postoperative recovery and rehabilitation. If feasible and if the mental skills training program shows promising effect on athletes' confidence in returning to sport, a large-scale clinical trial can be explored to assess the relationship between mental skills' impact on readiness to return to sport, which could in turn provide evidence on the benefits of integrating mental skills directly into standard clinical care.

NCT ID: NCT05338307 Active, not recruiting - Colorectal Cancer Clinical Trials

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention

BHB-CRC
Start date: May 13, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.